Pharmaceutical company Mylan has faced heat after news broke about the company increasing EpiPen's price by more than 450 percent since 2004, prompting the company to offer a generic product, according to CNBC.
Here are four things to know:
1. In 2008, EpiPen cost nearly $100, with the drug's current list price totaling $600.
2. Legislators and public officials, including Democratic presidential nominee Hillary Clinton, have critiqued Mylan, arguing the company's move to reduce some patients' out-of-pocket costs for the drug did not go far enough.
3. Mylan is launching an EpiPen generic alterative in the coming weeks with a $300 list price.
4. Chief Executive Heather Bresch said the company needed to price the drug high as it spent millions of dollars working to improve the drug, saying, "Our decision to launch a generic alternative to EpiPen is an extraordinary commercial response. We determined that bypassing the brand system in this case and offering an additional alternative was the best option."
More articles on quality & infection control:
The Joint Commission reports 47 patient falls, 52 unintended retained foreign objects in 2016 — 10 statistics on sentinel events
A conflict of interest? Mylan executive under fire for 400% EpiPen price hike
Harvard researchers have nearly recoded E. coli bacterium — 5 things to know about the virus-resistant genome
